Connect with us

Hi, what are you looking for?

Jewish Business News

Money

XTL Bio returns to Nasdaq

XTL’s lead product is a treatment of multiple myeloma, and it is readying a clinical trial for the product.

innerTopTitle

/ By Gali Weinreb / 

XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB); TASE:XTL) will resume trading on Nasdaq this week, after Nasdaq approved the company’s listing application last week. XTL’s ADR will be traded at a ratio of 20 shares representing each ADR.
XTL had been listed on Nasdaq, as well as the Tel Aviv Stock Exchange (TASE) and London Stock Exchange, until the collapse of its share price following the failure of the clinical trial of its lead product. The company delisted from London, and was relegated to the Pink Sheets on Wall Street.
Two years ago, XTL changed hands, replaced its management, and entered a new business. It has now reached a market cap and capital to return to Nasdaq. Its lead product is recombinant erythropoietin (rHuEPO) for the treatment of multiple myeloma, and it is readying a clinical trial for the product.
Published by www.globes-online.com 

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

empty

The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

Business

Now Platika joins and elite club of $10 billion plus Israeli firms.

Advertisement